Equelle provides clinically studied multi-symptom menopause relief.[a]

1. Equelle is associated with a reduction in hot flashes.

In a double-blind, active comparator trial in postmenopausal women (N=102), Equelle provided clinically meaningful reductions in daily hot flash frequency as early as week 4[b]

- Reductions in hot flash frequency was clinically meaningful at Week 4 (P=0.063), with continued reduction through Week 8
- Patients receiving Equelle experienced approximately 5 fewer hot flashes per day at Week 8 in comparison to 10.4 hot flashes per day at baseline

Mean change from baseline in daily hot flash frequency in the high vasomotor symptoms subgroup



2. Equelle improves muscle and joint aches and pains.

In a multicenter, double-blind placebo-controlled trial (N=160) with 12 weeks of intervention (placebo or S-equol), Equelle provided statistically significant reductions in[c]:

- Neck or shoulder muscle stiffness as early as week 12 (P=0.004 vs baseline)

Change in Visual Analog Scale (VAS) in neck or shoulder muscle stiffness in S-equol vs placebo[1]



3. Equelle improves sleep quality and duration.

In a randomized, placebo-controlled, double-blind, parallel study (N=118), significant improvements in sleep quality from baseline were observed as early as Week 4 in poor sleepers as measured by the Pittsburgh Sleep Quality Index[d]

- Sleep quality continued to improve significantly from baseline for the duration of the 12 weeks, with an additional 50 minutes of sleep per night at Week 12 (P=0.013 vs baseline)
- Sleep minutes were calculated using the Motionlogger Micro Watch (a wearable sleep tracker) that patients wore at home for a week at a time to measure changes in sleep
- Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI), which is a 19-item questionnaire designed to measure sleep disturbance

Change in sleep (min) from baseline to Week 12(n=118)



4. Equelle reduces vaginal irritation, itching, and soreness.

In a randomized, placebo-controlled, double-blind, parallel study (N=118), Equelle significantly improved vaginal symptoms for patients with 9 or more daily vasomotor symptoms vs placebo[d]

Change in vaginal symptoms from baseline at Week 12 (n=58)

5. Equelle alleviates mood swings.

In a randomized, placebo-controlled, double-blind, parallel study (N=118), patients with frequent vasomotor symptoms saw a significant improvement in emotional well-being after 12 weeks vs placebo (P=0.049)[d]

- Both total mood disturbance and vigor activity were also significantly improved compared with placebo (P=0.049, P=0.017, respectively)
- Patients with high vasomotor symptoms also showed a significant reduction in anger hostility vs placebo (P=0.049)
- Emotional well-being was measured by RAND-36, a well-validated health-related quality of life survey, and the Profile of Mood States (POMS-2)

Change in emotional well-being at Week 12 (n=58) measured by RAND-36, a well validated QOL questionnaire



6. Women using Equelle reported a high rate of satisfaction.

In the IHUT (In-Home-Usage-Test) Sample Trial, patients (US women with menopause symptoms for greater than ≥1 month, not on hormone therapy, no soy allergies) completed online surveys at Screening, Week 3, Week 7, and Week 12 after qualifying and receiving free EQUELLE product for daily consumption[e]

Results:

- 4 out of 5 women were satisfied with Equelle by week 3 (N=130)
- 92% of patients were satisfied with Equelle after 12 weeks (N=45)
- 94% of women noticed a difference and felt an improvement in a specific symptom
  - Hot flash
  - Night sweat
  - Sleep disturbance

a. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

b. Jenks BH, et al. J Womens Health (Larchmt). 2012;21(6):674-682.

c. Aso T, et al. J Womens Health (Larchmt). 2012;21(1):92-100. 2. Jenks BH, et al. J Womens Health (Larchmt). 2012;21(6):674-682.

d. Data on file. 1811 Study Report. Pharmavite LLC.

e. Data on file. In-Home Usage Test. Pharmavite LLC.